|
US5525464A
(en)
|
1987-04-01 |
1996-06-11 |
Hyseq, Inc. |
Method of sequencing by hybridization of oligonucleotide probes
|
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
|
US5700637A
(en)
|
1988-05-03 |
1997-12-23 |
Isis Innovation Limited |
Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
|
|
US6054270A
(en)
|
1988-05-03 |
2000-04-25 |
Oxford Gene Technology Limited |
Analying polynucleotide sequences
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
US5744101A
(en)
|
1989-06-07 |
1998-04-28 |
Affymax Technologies N.V. |
Photolabile nucleoside protecting groups
|
|
US5800992A
(en)
|
1989-06-07 |
1998-09-01 |
Fodor; Stephen P.A. |
Method of detecting nucleic acids
|
|
US5871928A
(en)
|
1989-06-07 |
1999-02-16 |
Fodor; Stephen P. A. |
Methods for nucleic acid analysis
|
|
AU675054B2
(en)
|
1991-11-22 |
1997-01-23 |
Affymetrix, Inc. |
Combinatorial strategies for polymer synthesis
|
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
|
US5795716A
(en)
|
1994-10-21 |
1998-08-18 |
Chee; Mark S. |
Computer-aided visualization and analysis system for sequence evaluation
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
US20020065296A1
(en)
|
1999-01-13 |
2002-05-30 |
Bayer Corporation |
Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
|
|
WO2000042012A1
(en)
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
|
ATE538794T1
(de)
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
US7141581B2
(en)
|
1999-07-02 |
2006-11-28 |
Agouron Pharmaceuticals, Inc. |
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
|
|
TWI262914B
(en)
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
|
EE05330B1
(et)
|
1999-11-05 |
2010-08-16 |
Astrazeneca Ab |
Kinasoliini derivaadid kui VEGF-i inhibiitorid
|
|
ES2267605T3
(es)
|
1999-12-22 |
2007-03-16 |
Sugen, Inc. |
Uso de compuestos de indolinona para la fabricacion de productos farmaceuticos destinados a modular la funcion de la c-kit-tirosina-proteina-quinasa.
|
|
US6573293B2
(en)
|
2000-02-15 |
2003-06-03 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
|
EP1343782B1
(en)
|
2000-12-21 |
2009-05-06 |
SmithKline Beecham Corporation |
Pyrimidineamines as angiogenesis modulators
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
ES2400070T3
(es)
|
2001-12-03 |
2013-04-05 |
Bayer Healthcare Llc |
Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
|
|
SE0104164L
(sv)
|
2001-12-11 |
2003-06-12 |
Ericsson Telefon Ab L M |
Högspännings-mos-transistor
|
|
NO317200B1
(no)
|
2002-08-09 |
2004-09-13 |
Best Practice Deployment As |
System for trafikkopplaering i et kjoretoy
|
|
WO2004029287A2
(en)
|
2002-09-27 |
2004-04-08 |
Oridis Biomed Forschungs- Und Entwicklungs Gmbh |
Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
|
|
KR20060031809A
(ko)
*
|
2003-06-09 |
2006-04-13 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
암 치료 및 진단용 조성물 및 방법
|
|
WO2005030140A2
(en)
|
2003-09-26 |
2005-04-07 |
Exelixis, Inc. |
C-met modulators and methods of use
|
|
GB0411378D0
(en)
|
2004-05-21 |
2004-06-23 |
Astrazeneca Ab |
Pharmaceutical compositions
|
|
WO2006138275A2
(en)
|
2005-06-13 |
2006-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
|
WO2007047955A2
(en)
|
2005-10-21 |
2007-04-26 |
Bayer Healthcare Llc |
Methods for prediction and prognosis of cancer, and monitoring cancer therapy
|
|
US8329408B2
(en)
|
2005-10-31 |
2012-12-11 |
Bayer Healthcare Llc |
Methods for prognosis and monitoring cancer therapy
|
|
EP1954272A2
(en)
|
2005-10-31 |
2008-08-13 |
Bayer Pharmaceuticals Corporation |
Treatment of cancer with sorafenib
|
|
EP2049084A2
(en)
|
2006-07-10 |
2009-04-22 |
Elan Pharma International Limited |
Nanoparticulate sorafenib formulations
|
|
RU2009114745A
(ru)
*
|
2006-09-19 |
2010-10-27 |
Новартис АГ (CH) |
Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования
|
|
AU2008279027B8
(en)
*
|
2007-07-25 |
2014-03-06 |
Eisai R & D Management Co., Ltd. |
Multikinase inhibitors for use in the treatment of cancer
|
|
US20090062347A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched axitinib
|
|
US20090062368A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sunitinib
|
|
NZ583790A
(en)
|
2007-09-10 |
2012-04-27 |
Cipla Ltd |
Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process
|
|
RU2505603C2
(ru)
|
2007-09-26 |
2014-01-27 |
Чугаи Сейяку Кабусики Кайся |
Антитело против рецептора il-6
|
|
WO2009054004A2
(en)
|
2007-10-22 |
2009-04-30 |
Natco Pharma Limited |
Process for the preparation of sorafenib
|
|
US20100256392A1
(en)
|
2007-11-21 |
2010-10-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
|
EP2220071A2
(en)
|
2007-11-21 |
2010-08-25 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
|
|
AU2009215377A1
(en)
|
2008-02-21 |
2009-08-27 |
Generics [Uk] Limited |
Novel polymorphs and processes for their preparation
|
|
WO2009106825A1
(en)
|
2008-02-27 |
2009-09-03 |
Cipla Limited |
Polymorphs of sorafenib and salts thereof
|
|
EP2098521A1
(en)
|
2008-03-06 |
2009-09-09 |
Ratiopharm GmbH |
Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
|
|
WO2009111061A1
(en)
|
2008-03-06 |
2009-09-11 |
Sicor Inc. |
Process for the preparation of sorafenib and salts thereof
|
|
CA2720164A1
(en)
|
2008-03-31 |
2009-10-08 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing sunitinib and salts thereof
|
|
US8501962B2
(en)
|
2008-06-23 |
2013-08-06 |
Natco Pharma Limited |
Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
|
|
WO2010011834A2
(en)
|
2008-07-24 |
2010-01-28 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib and salts thereof and their polymorphs
|
|
US20110301113A1
(en)
|
2008-09-26 |
2011-12-08 |
Concert Pharmaceuticals Inc. |
Pyridineamine derivatives
|
|
KR20100051769A
(ko)
|
2008-09-30 |
2010-05-18 |
테바 파마슈티컬 인더스트리즈 리미티드 |
수니티닙 베이스 및 ｌ-말산의 비정질 조성물
|
|
CA2741087A1
(en)
*
|
2008-10-21 |
2010-04-29 |
Bayer Healthcare Llc |
Identification of signature genes associated with hepatocellular carcinoma
|
|
EP2181991A1
(en)
|
2008-10-28 |
2010-05-05 |
LEK Pharmaceuticals D.D. |
Novel salts of sunitinib
|
|
EP2186809A1
(en)
|
2008-11-13 |
2010-05-19 |
LEK Pharmaceuticals D.D. |
New crystal form of sunitinib malate
|
|
EP2366162A1
(en)
*
|
2008-11-18 |
2011-09-21 |
Collabrx, Inc. |
Individualized cancer treatment
|
|
WO2010135608A1
(en)
*
|
2009-05-20 |
2010-11-25 |
Nodality, Inc. |
Methods for diagnosis, prognosis and methods of treatment
|
|
WO2011004200A1
(en)
|
2009-07-10 |
2011-01-13 |
Generics [Uk] Limited |
Novel pyrrole derivatives
|
|
JP2012533562A
(ja)
|
2009-07-16 |
2012-12-27 |
グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド |
治療法
|
|
US20120232102A1
(en)
|
2009-09-30 |
2012-09-13 |
Chun-Fang Xu |
Methods Of Administration And Treatment
|
|
CN102665756A
(zh)
|
2009-10-01 |
2012-09-12 |
Csl有限公司 |
费城染色体阳性白血病的治疗方法
|
|
WO2011047019A1
(en)
*
|
2009-10-13 |
2011-04-21 |
Yale University |
An objective, quantitative method to predict histological subtype in non-small cell lung cancer
|
|
WO2011050159A1
(en)
|
2009-10-23 |
2011-04-28 |
Glaxo Wellcome Manufacturing Pte Ltd |
Compositions and processes
|
|
UY33164A
(es)
|
2010-01-06 |
2011-08-31 |
Glaxo Wellcome Mfg Pte Ltd |
Metodo de tratamiento
|
|
WO2011100325A2
(en)
|
2010-02-09 |
2011-08-18 |
Sicor Inc. |
Polymorphs of sunitinib salts
|
|
WO2011104555A2
(en)
|
2010-02-25 |
2011-09-01 |
Generics [Uk] Limited |
Novel process
|
|
WO2011128699A2
(en)
|
2010-04-16 |
2011-10-20 |
Generics [Uk] Limited |
Novel process
|
|
TW201206908A
(en)
|
2010-05-05 |
2012-02-16 |
Glaxo Wellcome Mfg Pte Ltd |
Pharmaceutical compositions and methods of making same
|
|
WO2011146458A1
(en)
|
2010-05-18 |
2011-11-24 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
|
ES2643851T3
(es)
|
2010-11-01 |
2017-11-24 |
Scinopharm (Kunshan) Biochemical Technology Co., Ltd. |
Procedimientos para la preparación de 3-((pirrol-2-il)metilen)-2-pirrolonas usando 2-sililoxi-pirroles
|
|
WO2012073254A1
(en)
|
2010-11-29 |
2012-06-07 |
Hetero Research Foundation |
A process for the preparation of pazopanib using novel intermediate
|
|
EP2654797B1
(en)
|
2010-12-23 |
2017-11-08 |
Nektar Therapeutics |
Polymer-des-ethyl sunitinib conjugates
|
|
WO2012103060A1
(en)
|
2011-01-27 |
2012-08-02 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
|
WO2012116040A1
(en)
*
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
CN102283836B
(zh)
*
|
2011-06-27 |
2013-01-09 |
苏州大学附属第一医院 |
索拉非尼在制备治疗动脉瘤性自发性蛛网膜下腔出血后发生的早期脑损伤的药物中的应用
|
|
WO2013000909A1
(en)
|
2011-06-28 |
2013-01-03 |
Bayer Intellectual Property Gmbh |
Topical ophthalmological pharmaceutical composition containing sorafenib
|
|
KR20140067001A
(ko)
*
|
2011-08-08 |
2014-06-03 |
카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. |
생물지표 조성물 및 방법
|
|
WO2013043529A1
(en)
|
2011-09-19 |
2013-03-28 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
|
KR20140069297A
(ko)
|
2011-09-30 |
2014-06-09 |
화이자 인코포레이티드 |
N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물
|
|
US20140322166A1
(en)
*
|
2011-12-12 |
2014-10-30 |
Stc. Unm |
Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia
|
|
US20140087362A1
(en)
*
|
2012-03-16 |
2014-03-27 |
Aladar A. Szalay |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
US11136625B2
(en)
|
2013-08-28 |
2021-10-05 |
Crown Bioscience, Inc. (Taicang) |
Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
|